Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 9/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | FABP4 | P15090 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.43 |
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.42 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6988101 | 0.97 | FABP4 (0.50) | HCRTR1HCRTR2CYP3A4FABP4NAMPT | |
| SCHEMBL6989168 | 0.89 | DAGLA (0.48) | HCRTR1HCRTR2FABP4NAMPTSCD5 | |
| SCHEMBL6989978 | 0.88 | SCD5 (0.51) | HCRTR1HCRTR2CYP3A4FABP4SCD5 | |
| SCHEMBL6988586 | 0.88 | FABP4 (0.52) | HCRTR1HCRTR2CYP3A4FABP4NAMPT | |
| SCHEMBL3699136 | 0.88 | FABP4 (0.56) | HCRTR1HCRTR2CYP3A4FABP4SCD5 | |
| SCHEMBL6986822 | 0.88 | HCRTR1 (0.52) | HCRTR1HCRTR2CYP3A4FABP4 | |
| SCHEMBL3702050 | 0.88 | FABP4 (0.56) | HCRTR1HCRTR2CYP3A4FABP4SCD5 | |
| SCHEMBL3699134 | 0.88 | FABP4 (0.56) | HCRTR1HCRTR2CYP3A4FABP4SCD5 | |
| SCHEMBL6988396 | 0.87 | HRH3 (0.47) | HCRTR1HCRTR2CYP3A4FABP4SCD5 | |
| SCHEMBL6989348 | 0.87 | HCRTR1 (0.51) | HCRTR1HCRTR2CYP3A4FABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889683-B2 | Substituted quinoxalines as inhibitors of fatty acid binding protein | MERCK SHARP & DOHME CORP. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889683-B2 | Substituted quinoxalines as inhibitors of fatty acid binding protein | MERCK SHARP & DOHME CORP. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | MERCK SHARP & DOHME LLC | 2012-05-17 | — | — | US | disclosed |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | MERCK SHARP & DOHME LLC | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | FABP4, FABP1, FABP3 | HCRTR1 4346/4885HCRTR2 3592/4885CYP3A4 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.